Could an antibody boost chemo for tough blood cancers?

NCT ID NCT07072585

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a protein on cancer cells, helping the immune system attack them. The study will compare event-free survival between those who get chemo alone and those who get chemo plus daratumumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Daratumumab (a monoclonal antibody) added to standard chemotherapy
What this could lead to
If successful, this could lead to a more effective first-line treatment for T-ALL and T-LL, potentially improving long-term survival rates.
What could go wrong
This is a large but still experimental trial. Daratumumab may not improve outcomes over chemotherapy alone, and side effects from adding it could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE II T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.